GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenxbio Inc (NAS:RGNX) » Definitions » Price-to-Owner-Earnings

Regenxbio (Regenxbio) Price-to-Owner-Earnings : (As of May. 12, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Regenxbio Price-to-Owner-Earnings?

As of today (2024-05-12), Regenxbio's share price is $15.44. Regenxbio does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Regenxbio's Price-to-Owner-Earnings or its related term are showing as below:

During the past 11 years, the highest Price-to-Owner-Earnings of Regenxbio was 2695.00. The lowest was 5.92. And the median was 10.03.


RGNX's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 35.03
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-12), Regenxbio's share price is $15.44. Regenxbio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-5.87. Therefore, Regenxbio's PE Ratio for today is At Loss.

As of today (2024-05-12), Regenxbio's share price is $15.44. Regenxbio's EPS without NRI for the trailing twelve months (TTM) ended in was $-6.09. Therefore, Regenxbio's PE Ratio without NRI for today is At Loss.

During the past 11 years, Regenxbio's highest PE Ratio without NRI was 54.85. The lowest was 0.00. And the median was 17.64.


Regenxbio Price-to-Owner-Earnings Historical Data

The historical data trend for Regenxbio's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenxbio Price-to-Owner-Earnings Chart

Regenxbio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 10.21 - -

Regenxbio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Regenxbio's Price-to-Owner-Earnings

For the Biotechnology subindustry, Regenxbio's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenxbio's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenxbio's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Regenxbio's Price-to-Owner-Earnings falls into.



Regenxbio Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Regenxbio's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=15.44/-5.63
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regenxbio  (NAS:RGNX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Regenxbio Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Regenxbio's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenxbio (Regenxbio) Business Description

Traded in Other Exchanges
Address
9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa).
Executives
Kenneth T. Mills director, officer: See Remarks C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Vittal Vasista officer: See Remarks C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Jennifer Zachary director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Steve Pakola officer: Chief Medical Officer C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Allan M. Fox director, 10 percent owner C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Jean Bennett director C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
George V Migausky director C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Patrick J. Christmas officer: Senior VP, General Counsel C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Curran Simpson officer: SVP of Technical Operations C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Hayden Donald J Jr director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Olivier Danos officer: Chief Scientific Officer C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Luke M Beshar director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Stephen Yoo officer: Chief Medical Officer C/O REGENXBIO INC,, 9600 BLACKWELL ROAD, SUITE 210, ROCKVILLE MD 20850
Alexandra Glucksmann director C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Daniel Tasse director C/O IKARIA, INC., 6 STATE ROUTE 173, CLINTON NJ 08809